CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $111,048.96 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 2,112 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $52.58, for a total value of $111,048.96. Following the completion of the sale, the general counsel owned 85,115 shares of the company’s stock, valued at approximately $4,475,346.70. This represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

CRISPR Therapeutics Trading Down 2.2%

CRSP stock traded down $1.18 during trading on Friday, reaching $53.46. 1,297,432 shares of the stock were exchanged, compared to its average volume of 1,744,686. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48. The firm’s 50 day moving average is $53.90 and its 200 day moving average is $57.27. The firm has a market cap of $5.13 billion, a P/E ratio of -8.20 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $4.72 million. During the same quarter in the prior year, the firm earned ($1.01) EPS. The company’s revenue was down 97.8% compared to the same quarter last year. As a group, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on CRSP shares. Needham & Company LLC boosted their target price on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. Citizens Jmp lowered their price objective on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a research note on Friday, January 30th. Citigroup restated a “buy” rating on shares of CRISPR Therapeutics in a report on Monday. Chardan Capital upped their price target on CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a report on Saturday, February 14th. Finally, Robert W. Baird lowered their price target on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $64.24.

Institutional Trading of CRISPR Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in CRISPR Therapeutics by 5.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after acquiring an additional 180 shares during the last quarter. Cerity Partners LLC grew its holdings in CRISPR Therapeutics by 3.0% during the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after purchasing an additional 190 shares during the period. Peapack Gladstone Financial Corp increased its position in CRISPR Therapeutics by 3.0% in the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after buying an additional 200 shares during the last quarter. Optiver Holding B.V. raised its stake in shares of CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after buying an additional 210 shares during the period. Finally, Ipswich Investment Management Co. Inc. lifted its position in shares of CRISPR Therapeutics by 0.9% during the 3rd quarter. Ipswich Investment Management Co. Inc. now owns 25,198 shares of the company’s stock valued at $1,633,000 after buying an additional 230 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.